The Life Sciences Innovative Manufacturing Fund (LSIMF) is part of the Global Britain Investment Fund, of which £354 million will support life sciences manufacturing.
The LSIMF will provide £60 million in capital grants for investment in the manufacture of:
We particularly encourage applications from companies ready to deploy their emerging technologies at scale in commercial manufacturing.
Your manufacturing investment must relate to the manufacture of: Human medicines (this includes both the manufacture of active pharmaceutical ingredients (API) / drug substance and finished product / drug product). The fund is open to applications across the breadth of types of MHRA licensed medicines for human use, OR
Diagnostics – for both disease identification and monitoring in human health, OR
Medical devices – all types of medical devices related to human health
Your project must: Be a manufacturing project: this could be manufacturing product for clinical trials or for commercial sale, AND
Be located in the UK, AND
Have a total investment value of more than £12 million
Your project can: Be for the upgrade or expansion of an existing facility or the establishment of a new manufacturing facility
Applicants will be prioritised based on their alignment to the fund’s objectives:
Applications are welcome from companies developing highly innovative products such as:
In addition, we particularly welcome applications that include the adoption of innovative process technologies, such as: